🔗 Share this article

As the US continues making sweeping revisions to its vaccination schedules, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the global health crisis and has concentrated on potential deaths after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to announce major changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of step with much of the world with little proof for benefit. This reveal has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for halting certain pediatric immunization guidelines in the US to become more similar to Denmark, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – usually the purview of Prasad, director of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

Høeg has no apparent background in pharmaceutical research, regulation or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an enormous portfolio at the agency, Woodcock pointed out.

“The public just focuses on the innovative therapies, but the off-patent medication office approves a multitude of generic drugs. There is also a biosimilars division, OTC medication office and other areas, and every single one must be managed,” she explained. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial management component to the job, which oversees over 5,000 personnel. “It is a enormous leadership role, if you execute it properly,” she added.

Response and Controversial Initiatives

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection represents more teamwork among agency officials on vaccines, a representative responded that the “inquiries are based on inaccurate presumptions”.

“Her experience aligns with the duties of her role,” the spokesperson stated, citing the period Dr. Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new priority voucher program, a controversial rapid therapy clearance system that allegedly troubled her preceding directors. “How are these therapies being selected for this voucher program? Who makes the calls?” Dr. Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA appears to be shifting towards less stringent regulations of all drugs, except for shots.”

Established History on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, Howard observe. She authored a analysis using non-validated volunteer-provided data to determine the rate of heart inflammation following COVID-19 vaccination. She advised the Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the current administration encompassed revising regulations for recently developed shots and halting “non-essential” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has reportedly proposed barring adolescent males from obtaining Covid vaccinations.

“She’s an thorough true believer who starts off with her beliefs and tailors the evidence to accommodate the evidence in a extremely misleading, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|